Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Vitrolife

Vitrolife

Read in Swedish

Vitrolife AB (publ): Report on Operations 2019: High Time-lapse growth

08:30 / 6 February 2020 Vitrolife Press release

Fourth quarter
  • Sales amounted to SEK 409 (320) million, corresponding to an increase of 28 percent in SEK. Sales increased by 21 percent in local currency whereof 11 percent comprised organic growth.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 160 (135) million, corresponding to a margin of 39 (42) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 7 million.
  • Net income amounted to SEK 96 (84) million, which gave earnings per share of SEK 0.89 (0.77).
Whole year 2019
  • Sales amounted to SEK 1 480 (1 151) million, corresponding to an increase of 29 percent in SEK. Sales increased by 22 percent in local currency whereof 12 percent comprised organic growth.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 587 (479) million, corresponding to a margin of 40 (42) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 37 million.
  • Net income amounted to SEK 384 (311) million, which gave earnings per share of SEK 3.53 (2.85).
After the end of the period
  • The Board proposes a dividend of SEK 114 (92) million, corresponding to SEK 1.05 (0.85) per share.

Gothenburg, February 6, 2020
VITROLIFE AB (publ)
Thomas Axelsson, CEO

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com.Website: www.vitrolife.com/

Show as PDF

Show original from Cision

Cision

This information was distributed by Cision http://www.cisionwire.se/